Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.

JCO precision oncology - 1 Jan 2021

Hendifar Andrew, Blais Edik M, Wolpin Brian, Subbiah Vivek, Collisson Eric, Singh Isha, Cannon Timothy, Shaw Kenna, Petricoin Emanuel F, Klempner Samuel, Lyons Emily, Wang-Gillam Andrea, Pishvaian Michael J, O'Reilly Eileen M

Abstract excerpt

PURPOSE: In pancreatic cancer (PC), the RAF family alterations define a rare subset of patients that may predict response to inhibition of the BRAF/MEK/ERK signaling pathway. A comprehensive understanding of the molecular and clinical characteristics of RAF-mutated PC may support future development of RAF-directed strategies. METHODS: Clinical outcomes were assessed across a multi-institutional case series of 81...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Neoplasm Metastasis

Share to Pancreatic Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 34476331
DOI: 10.1200/PO.20.00494
PMCID: PMC8407652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.PMID 34476331Read ↗

Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent <i>RAF</i> Fusions and Frequent Inactivation of DNA Repair GenesSemantic proximity Read ↗

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities.Semantic proximity Read ↗

Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports.Semantic proximity Read ↗

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Successful BRAF/MEK inhibition in a patient with BRAFV600E-mutated extrapancreatic acinar cell carcinoma.Semantic proximity Read ↗

Near complete remission of an inoperable pancreatic acinar cell carcinoma after BRAF-/MEK-inhibitor treatment-A case report and review of the literature.Semantic proximity Read ↗

Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review.Semantic proximity Read ↗

Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer.Semantic proximity Read ↗

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cellsSemantic proximity Read ↗

Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic CancerSemantic proximity Read ↗

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.Semantic proximity Read ↗

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.